Eli Lilly (LLY) announced a $3B expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year. This investment will extend the company’s global parenteral product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 jobs to the current 100-plus workforce at this location. The company plans to start construction on the expansion next year. The acquisition, expansion, and additional purchases of land and the adjacent warehouse bring Lilly’s total planned investment in Wisconsin to $4B. The expanded facility will focus on manufacturing injectable medicines, device assembly and packaging for medicines across multiple therapeutic areas. Lilly will use advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production. From data management to operations, digital automation will be embedded throughout the site to accelerate processes and increase accuracy. New jobs at the site will include operators, technicians, engineers and scientists – in addition to more than 2,000 construction jobs during the expansion project’s construction.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Dollar General reports mixed Q3, American Air raises Q4 outlook: Morning Buzz
- Trump Trade: Fiserv shares slip as CEO set to join new administration
- U.K. to limit Eli Lilly’s Mounjaro to patients with greatest need, STAT reports
- Eli Lilly CEO says he will fight for FDA , challenge Kennedy’s stance, NYT says
- Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
